Work

KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps4599

Authors: Toni K. Choueiri, David I. Quinn, Tian Zhang, Howard Gurney, Gurjyot K. Doshi, Patrick Wayne Cobb, Francis Parnis, Jae-Lyun Lee, Se Hoon Park, Andrey Semenov, Wayne Yen-Hwa Chang, Shuyan M. Wan, Christian Heinrich Poehlein, Thomas Powles

Institutions: Dana-Farber Cancer Institute, USC Norris Comprehensive Cancer Center, Duke University, Duke Cancer Institute, Macquarie University, St. Vincent's HealthCare, Asan Medical Center, University of Ulsan, Samsung Medical Center, Taipei Veterans General Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), Queen Mary University of London, Barts Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892290356

Cites:

Cited by: 19

Related to: 10